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Abstract
Introduction: The developmental origins of disease or fetal programming model predicts that 
intrauterine exposures have life-long consequences for physical and psychological health. Prenatal 
programming of the fetal hypothalamic-pituitary-adrenal (HPA) axis is proposed as a primary 
mechanism by which early experiences are linked to later disease risk.
Areas covered: This review describes the development of the fetal HPA axis, which is 
determined by an intricately timed cascade of endocrine events during gestation and is regulated 
by an integrated maternal-placental-fetal steroidogenic unit. Mechanisms by which stress-induced 
elevations in hormones of maternal, fetal, or placental origin influence the structure and function 
of the emerging fetal HPA axis are discussed. Recent prospective studies documenting persisting 
associations between prenatal stress exposures and altered postnatal HPA axis function are 
summarized, with effects observed beginning in infancy into adulthood.
Expert commentary: The results of these studies are synthesized, and potential moderating 
factors are discussed. Promising areas of further research highlighted include epigenetic 
mechanisms and interactions between pre and postnatal influences.
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1. Introduction
The fetal period is a critical window of development, during which the architecture of the 
brain and other organ systems are fundamentally shaped. Within the first month of gestation, 
regions of the central nervous system are already formed and differentiated. Prolific 
neurogenesis occurs, with the majority of the brain’s billions of neurons produced by mid-
gestation [1]. An intricately timed sequence of organizational processes ensues, including 
neuronal migration, differentiation, synaptogenesis, apoptosis, and myelination [2]. Because 
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the developing fetal brain is plastic, it is highly susceptible to in utero exposures and 
experiences.
The developmental origins of disease or fetal programming model predicts that early 
exposures to a variety of adverse events and signals have life-long consequences for physical 
and psychological health [3, 4]. Programming refers to the effects of an environmental signal 
acting during a sensitive developmental period to influence the construction of specific 
organ systems [3–5]. The developing fetus is sensitive and responsive to maternal 
nutritional, vascular, immune, and endocrine signals that convey information about the 
quality of the external environment. In response to these signals, the fetus adjusts its 
developmental trajectory to prepare for its anticipated life after birth. If signals convey 
conditions of deprivation or stress, the fetus may accelerate or reduce its growth, or shift 
resources to benefit certain systems at a cost to other systems [6, 7]. These developmental 
alterations may be adaptive. For instance, if the postnatal environment matches that 
predicted by the prenatal environment, the infant may be well-equipped for his or her 
environment and may thrive. If there is a mismatch, the risk for disease may increase [4, 5, 
8].
During fetal life, the hypothalamic-pituitary-adrenal (HPA) axis is under construction and 
therefore susceptible to prenatal programming influences. The fully mature HPA axis 
mobilizes the body’s physical and psychological resources in response to stress and 
regulates many homeostatic systems in the body, including the metabolic, cardiovascular, 
immune, reproductive, and central nervous systems. Given the central role of the HPA axis 
in many survival functions and links between HPA axis dysregulation and disease [9–15], 
programming of this system during fetal life is proposed as a primary mechanism by which 
early experiences are linked to later health outcomes [3, 16–22].
In this review, we examine evidence supporting the hypothesis that prenatal stress exposures 
shape the developing fetal HPA axis and represent a primary fetal programming mechanism. 
First, we describe the prenatal endocrine milieu in which the fetal HPA axis develops. We 
then delineate mechanisms by which fetal exposure to prenatal stress may influence the 
structure and function of the emerging HPA axis. Finally, we summarize existing literature 
concerning the effects of prenatal stress on postnatal HPA axis functioning, spanning infancy 
to adulthood. There is a well-established non-human animal literature documenting the 
programming influences of prenatal stress on offspring outcomes, including HPA axis 
functioning [23–26]. Human gestational physiology and fetal HPA axis development differ 
even from that of closely related nonhuman primates, thereby limiting the generalizability of 
animal models [27, 28]. Thus, this review will focus solely on studies of prenatal stress and 
fetal HPA axis development in humans.
2. Biological stress system
The human biological “fight or flight” stress response is triggered under conditions of threat 
to homeostasis and involves activation of the HPA axis, in coordination with the locus 
ceruleus-norepinephrine (LC-NE)/sympathetic and immune systems. The primary regulator 
of the HPA axis is the 41-amino acid neuropeptide corticotropin-releasing hormone (CRH). 
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CRH-producing neurons in paraventricular nucleus of the hypothalamus are innervated by 
afferent projections from multiple brain regions, including the brain stem, lamina terminalis, 
extra-PVN hypothalamic nuclei, and limbic structures, which respond to different physical 
and emotional stressors [29–31; see Figure 1]. CRH is secreted, along with arginine-
vasopressin (AVP), into the hypophyseal portal blood, via axons projecting to the median 
eminence. CRH binds to its receptors on corticotropes of the anterior pituitary, stimulating 
production of the 31K dalton prohormone proopiomelanocortin (POMC). POMC is cleaved 
by enzymes into adrenocorticotrophic hormone (ACTH) and other bioactive peptides. ACTH 
enters the bloodstream and induces secretion of the glucocorticoid steroid hormone cortisol 
from the zona fasciculata of the adrenal cortex (see Figure 1). This cascade of hormone 
events mobilizes the body’s physiological and psychological resources to cope with the 
stressor and maintain homeostasis.
Circulating cortisol exerts its effects by binding to two types of receptors, the type I, high-
affinity mineralocorticoid receptor (MR), and the type II, low-affinity glucocorticoid 
receptor (GR). Cortisol has a 10-fold higher affinity for MRs than for GRs, so at basal 
concentrations of cortisol, MRs are occupied and GRs remain largely unoccupied [32]. MRs 
are proposed to regulate the tonic actions of cortisol, including its normative diurnal rhythm 
and the sensitivity of the stress response, whereas GRs are increasingly occupied during 
periods of elevated cortisol in response to stress [10, 32–34]. The effects of stress-induced 
elevations in cortisol include activation and regulation of cardiovascular and immune 
systems, utilization of energy stores and gluconeogenesis, inhibition of feeding, 
reproductive, and growth functions, and enhancement of memory and attentional processes 
[9, 10, 18, 29, 35–37]. High levels of circulating cortisol inhibit further HPA activity by 
binding to GRs and MRs at the level of the hypothalamus, pituitary, and hippocampus [10, 
30]. Under normal conditions, this negative feedback loop terminates the stress response, 
because its adaptive function is to respond to and prepare for immediate challenges. 
Prolonged or chronic stress exposures may have adverse effects and result in dysregulation 
of the HPA axis [9, 36, 38, 39].
HPA axis dysregulation is associated with a variety of pathological conditions, including 
metabolic and cardiovascular disease, hypertension, obesity, osteoporosis, altered 
gastrointestinal and immune function, sleep disturbances, and affective disorders [9, 11–15, 
35, 37, 40–45]. Links between HPA axis functioning and disease states are likely complex 
and bidirectional, with HPA axis functioning serving as a risk factor for and/or a 
consequence of disease. Prospective, longitudinal studies provide evidence that HPA axis 
dysregulation precedes certain physical and psychological conditions. Higher diurnal 
cortisol output is predictive of increasing mental health symptoms across childhood [46], 
and higher cortisol awakening responses have been shown to predict onsets of anxiety and 
depressive disorders during adolescence and adulthood [47–52]. Blunted patterns of diurnal 
cortisol output have been associated with higher body mass index both concurrently and 
longitudinally during adolescence [53]. Higher diurnal cortisol output also prospectively 
predicts reduced hippocampal volume and memory deficits [54] as well as increased risk of 
cardiovascular-related mortality in older adults [55].
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3. Maternal-placental-fetal stress system
Examining the link between prenatal stress and fetal HPA axis development requires an 
understanding of the dramatic changes that occur in both the maternal and developing fetal 
stress systems during the prenatal period. The growth of a new organ, the placenta, is 
primarily responsible for these changes. The placenta is the interface and area of exchange 
of signals or information between the maternal and fetal compartments. The placenta 
additionally produces its own hormones, most of which are identical to those produced in 
endocrine tissue of the non-pregnant adult [56, 57]. These placental hormones bind to 
maternal hormone receptors and act as allocrine factors, adjusting maternal physiology to 
benefit both mother and fetus [58]. Among the many hormones produced by the placenta is 
CRH, the primary regulator of the stress response system. CRH mRNA is expressed in the 
placenta by the seventh week of gestation [59], is identical to hypothalamic CRH in 
structure, immunoreactivity, and bioreactivity, and is released into both maternal and fetal 
compartments [59–63]. Placental CRH is a primary regulator of stress hormone production 
during pregnancy and both influences and is influenced by maternal and fetal stress signals. 
As such, the prenatal stress response system may be best conceptualized as an integrated 
maternal-placental-fetal steroidogenic unit [58; see Figure 2].
3.1 Changes in the maternal stress system
Over course of gestation, maternal production of stress peptides and hormones increases 
several-fold, largely as a result of placental CRH production. Concentrations of circulating 
CRH in the maternal plasma are almost exclusively of placental origin. The minute 
quantities of maternal hypothalamic CRH released into circulation are rapidly degraded and 
largely undetectable [58, 64]. Placental CRH production rises exponentially over gestation 
and increases in maternal plasma up to 1,000 times its non-pregnant level [65, 66]. By the 
end of gestation, maternal placental CRH levels are equivalent to those observed in the 
hypothalamic system only during acute psychological stress [67].
Increased unbound placental CRH in maternal plasma stimulates the synthesis and release of 
maternal ACTH from the anterior pituitary and downstream production of cortisol from the 
adrenal glands [68–71]. Maternal plasma cortisol levels increase 3–5-fold over the course of 
gestation, reaching levels comparable to those observed in Cushing’s disease and certain 
psychopathological conditions [64, 66]. Unlike the negative feedback function of cortisol on 
CRH expression in the hypothalamus, maternal cortisol stimulates expression of CRH in the 
placenta [70]. A positive feedback loop is established, allowing for the simultaneous 
increase of placental CRH, ACTH, and cortisol in the maternal compartment over the course 
gestation [59, 66, 68, 70, 71; see Figures 2 and 3]. The maternal HPA axis is still subject to 
negative feedback inhibition, and as pregnancy advances towards term, increased levels of 
these hormones further blunt maternal HPA axis responsiveness to physiological and 
psychological stressors [72–78]. This dampening in stress responsivity likely serves an 
adaptive purpose, protecting the mother and her fetus from the deleterious effects of 
environmental stressors [72, 79, 80].
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3.2 Developing fetal stress system
Because the fetal stress system is immature, it relies heavily upon maternal and placental 
inputs, functioning more so as an endocrine network than a linear axis [81]. The structures 
of the emerging fetal HPA axis undergo tremendous growth and organization during the 
prenatal period, and as gestation advances, fetal stress hormone production is increasingly 
evident.
The fetal hypothalamus forms from the ventral diencephalon and is differentiated by 9–10 
weeks’ gestation (see refs. 82, 83). The primordium of the anterior pituitary, Rathke’s pouch, 
is formed from an invagination of oral ectoderm and is first evident at approximately 5 
weeks’ gestation (see refs. 58, 84–87). The hypothalamic-hypophyseal portal system is 
intact as early as 11 weeks’ gestation [88]. CRH immunoactivity and bioactivity are 
detectable in fetal hypothalamic tissue extracts as early as 12–13 weeks’ gestation, with 
bioactivity increasing as a function of gestational age [89]. CRH-immunoreactive fibers are 
present in the median eminence by 14–16 weeks’ gestation [90], and CRH immunoactivity 
is present in the fetal pituitary from 12 weeks’ gestation onwards [89]. The fetal 
hypothalamus therefore has the capacity to stimulate pituitary ACTH production from early 
in the second trimester. In vitro, fetal pituitary corticotrophs secrete significant amounts of 
ACTH as early as 8 weeks’ gestation [91, 92], and administration of synthetic CRH 
stimulates ACTH secretion by the pituitary as early as 14 weeks’ gestation [93, 94]. The 
extent to which endogenous fetal hypothalamic CRH is involved in regulating ACTH release 
in vivo remains uncertain [58]. Examination of endocrine profiles in preterm infants 
suggests that sequential release of hypothalamic CRH, ACTH and cortisol may not be 
established until late in gestation [95, 96].
The fetal adrenal cortex arises from the intermediate mesoderm. The adrenal primordium 
forms posteromedial to the urogenital ridge and is distinguishable at 33 days’ post-
conception [97–99]. By 8 weeks’ gestation, the distinct zones of the cortex are apparent, and 
by 9 weeks’ gestation, the cortex is completely encapsulated [27, 92, 97, 99]. The fetal 
adrenal cortex is active beginning early in gestation and is one of the most highly 
vascularized fetal organs [27]. Adrenal steroid hormones are involved in the regulation of 
intrauterine homeostasis and the maturation of organ systems [22, 27, 100]. De novo 
synthesis of cortisol from its precursor cholesterol requires the presence of specific 
steroidogenic enzymes, including 3β-hydroxysteroid dehydrogenase/Δ4−5 isomerase (3β-
HSD). A recent examination of first trimester fetal adrenals documented by 
immunohistochemistry a transient expression of 3β-HSD from approximately 7–10 weeks’ 
gestation [92]. Ex vivo tissue culture revealed cortisol synthesis regulated by ACTH and 
negative feedback apparent at the anterior pituitary. Therefore, early in gestation, de novo 
production of cortisol from cholesterol likely occurs briefly, which may function to regulate 
female sexual differentiation via inhibition of adrenal androgen production [92]. During 
most of the second trimester, fetal adrenal expression of 3β-HSD is suppressed [101–103]. 
From approximately 23–24 weeks onward, 3β-HSD and other requisite enzymes are again 
apparent, and cortisol production increases as gestation advances [101–103].
In addition to the patterning of steroidogenic enzymes, placental factors regulating fetal 
exposure to maternal cortisol are hypothesized to influence the timing of fetal pituitary-
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adrenal activity. From early to mid-gestation, transfer of maternal cortisol to the fetus may 
function to suppress fetal ACTH production [104]. As gestation advances, increasing levels 
of the placental enzyme 11β-hydroxysteroid dehydrogenase 2 (11β-HSD-2) oxidize 
maternal cortisol into its metabolite cortisone, which does not act on glucocorticoid 
receptors [105–110]. Reduced maternal cortisol in the fetal circulation may then disinhibit 
the fetal pituitary, resulting in increased ACTH production [104, 107]. ACTH secreted from 
the fetal pituitary is the primary regulator of fetal adrenocortical development, stimulating 
the proliferation of adrenocortical cells in vivo [27].
However, rising levels of fetal cortisol over the second half of gestation [111–113] are not 
paralleled by large increases in fetal ACTH [111, 114]. Evidence suggests that placental 
hormones, particularly placental CRH, play a central role in regulating fetal adrenal 
development. Both the fetal pituitary and adrenal glands express CRH receptors [115, 116]. 
In vitro, CRH up-regulates ACTH receptor expression in isolated fetal adrenal cells [117]. 
Increasing levels of placental CRH could therefore enhance adrenal responsiveness to 
ACTH, promoting adrenal cortisol synthesis despite the limited availability of circulating 
fetal ACTH [117]. Placental CRH also may directly regulate adrenal cortisol production, as 
CRH stimulates cortisol synthesis and expression of requisite steroidogenic enzymes in 
isolated fetal adrenal cells [118, 119]. Increased fetal cortisol would in turn increase 
placental CRH levels, forming a positive feedback loop parallel to that of maternal cortisol 
and placental CRH [27, 70]. Higher levels of CRH in the umbilical vein as compared to the 
umbilical artery suggest that CRH in the fetal circulation is largely of placental origin [61].
Although the likely multiple mechanisms by which fetal cortisol production is regulated are 
not fully understood, escalation of fetal cortisol production from the end of the second 
trimester through the third trimester is evident [111–113]. By 30 weeks, the fetal adrenal 
cortex resembles a rudimentary form of the adult adrenal cortex [120]. Late in pregnancy, at 
approximately 34–35 weeks’ gestation, levels of 11β-HSD-2 decrease [107, 108, 121], 
allowing for greater transfer of maternal cortisol into the fetal compartment. Increased 
maternal cortisol in the fetal circulation would suppress fetal ACTH production. The 
increased transfer of maternal cortisol to the fetus is thought to constitute a back-up 
mechanism to ensure fetal organ maturation and may explain why fetuses with 
glucocorticoid deficiencies are born without signs of organ immaturity [27, 58]. By term, 
approximately 75% of the cortisol in fetal circulation is of fetal origin, with the remaining 
25% of maternal origin [105]. In addition to ensuring adequate maturation of fetal organ 
systems, elevated maternal and fetal cortisol late in gestation may act to influence the timing 
of parturition [27, 70, 100, 121, 122].
4. Fetal exposure to prenatal stress hormones
Fetal exposure to maternal and placental stress hormones is considered a primary biological 
pathway by which various forms of prenatal psychological and biological stress influence 
the development of the fetal HPA axis. Maternal cortisol and placental CRH are key prenatal 
stress hormones which may program the emerging fetal HPA axis. The maternal-placental-
fetal steroidogenic unit produces massive amounts of these stress hormones during 
pregnancy. While exponential increases in these hormones are normative and necessary for 
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successful gestation and parturition, the fetus is vulnerable to further stress-induced 
increases in these hormones. In cases of extreme stress to the system and rapidly 
accelerating levels of stress hormones, especially placental CRH, preterm birth may result 
[66, 123, 124]. Increasing evidence suggests that stress-induced increases in hormones also 
exert programming influences on fetal HPA axis development independent of birth 
phenotype.
4.1 Exposure to maternal cortisol
The effects of elevated maternal cortisol appear to be dependent upon the timing of 
exposure. As previously stated, the fetus is less protected from maternal cortisol during early 
and late gestation, when placental 11β-HSD-2 levels are lower [105–109, 121]. Excess 
maternal cortisol during early to mid-gestation appears to exert negative effects on the fetus, 
whereas elevated maternal cortisol near term is beneficial, promoting fetal organ maturation 
and enhanced neurodevelopment [125–129]. Although 11β-HSD-2 limits fetal exposure to 
maternal cortisol as gestation advances, it is only partial barrier [130, 131], with 
approximately 15% of maternal cortisol crossing through the placenta unmetabolized [106, 
131, 132]. Mid to late-gestational maternal and fetal cortisol levels are correlated, with 
approximately 40% of their variance shared [130, 131]. Additional associations have been 
documented between maternal cortisol and amniotic fluid cortisol [133] and between 
maternal and neonatal ACTH and cortisol levels at birth [134].
Because some maternal cortisol does reach the fetus, elevations in maternal cortisol in 
response to physical or psychological stress may subsequently elevate cortisol levels in the 
fetal circulation [106, 111, 130, 131, 135]. Increased maternal stress also may increase fetal 
exposure to cortisol by downregulating placental 11β-HSD-2 activity, thus allowing a 
greater proportion of maternal cortisol to cross into the placenta and then enter fetal 
circulation. Several key biological stress signals act to downregulate placental 11β-HSD-2, 
including catecholamines [136], proinflammatory cytokines [137, 138], and hypoxic factors 
[139]. Prenatal maternal anxiety and depressive symptoms are respectively associated with 
reduced placental 11β-HSD-2 gene expression and activity [140]. Decreased 11β-HSD-2 
activity may account for the greater concordance observed between maternal and amniotic 
fluid cortisol as a function increased maternal anxiety [141].
Exposure to excessive concentrations of cortisol could alter glucocorticoid receptor density 
and function at each level of the fetal HPA axis, thereby calibrating the sensitivity of the 
system to feedback mechanisms [23, 142]. Glucocorticoid receptors are highly expressed 
throughout the developing brain, particularly so in regions providing excitatory (e.g., 
amygdala) and inhibitory (e.g., hippocampus) inputs to the HPA axis [22, 24, 30, 143–147]. 
GRs and MRs are abundant in the hippocampus [10, 32], with both receptor types expressed 
in this region as early as 24 weeks’ gestation [147]. Prenatal glucocorticoid exposure is 
associated with decreased hippocampal GR and MR density in non-human animals, 
resulting in decreased negative feedback regulation of the HPA axis [10, 142, 147–150]. 
Additional findings from animal models indicate that excess glucocorticoids alter the density 
of MRs and GRs and increase production of CRH in the amygdala, with increased forward 
drive to the axis [25, 142, 148]. In humans, exposure to elevated maternal cortisol early in 
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gestation is associated with increased volume of the right amygdala in female children [127]. 
The balance of GRs and MRs in the hippocampus and other brain regions is critical to HPA 
axis sensitivity, drive, and inhibition, with a GR/MR imbalance resulting in dysregulation of 
the axis and is implicated in depression and other psychopathological conditions [10, 151].
4.2 Exposure to placental CRH
Like the hypothalamus, the placenta produces CRH in response to stress. Unlike the negative 
feedback influence of cortisol on hypothalamic CRH expression, maternal and fetal cortisol 
stimulate placental CRH expression, constituting parallel positive feedback loops [27, 59, 
64, 68, 70]. Elevations in maternal cortisol may therefore act on fetal development indirectly 
through increased placental CRH production. In vivo, elevated levels of maternal cortisol 
early in gestation are associated with accelerated trajectories of placental CRH [66, 152]. 
CRH is also released from cultured human placental cells in a dose-response manner to a 
number of other major biological stress signals, including catecholamines, proinflammatory 
cytokines, and angiotensin-II [153, 154]. Consistent with these in vitro studies, stress-related 
intrauterine conditions such as reduced uterine blood flow, nutrient restriction, and infection 
are associated with increases in placental CRH [155–157]. Elevated placental CRH levels 
also are observed in women with higher maternal pregnancy-specific anxiety [158], 
perceived stress [159] and depressive symptoms [160–162], and in women with lower social 
support from family [163]. Thus, placental CRH may represent an integrative pathway by 
which various prenatal stressors of both maternal and fetal origin shape the developing fetal 
HPA axis.
As previously discussed, placental CRH likely acts to increase fetal cortisol production, both 
directly, by stimulation of the fetal adrenals, and indirectly, by increasing fetal adrenal 
responsiveness to ACTH [115–119]. Upregulated placental CRH via any of the biological 
stress signals promoting its production could therefore induce exaggerated fetal adrenal 
cortisol production or program the sensitivity of the adrenal glands to ACTH [70, 111, 118]. 
Elevated placental CRH in the fetal circulation presumably permeates the immature fetal 
blood-brain barrier [164], where CRH receptors are widely expressed from 13 weeks’ 
gestation [165]. CRH mRNA-expressing neurons are particularly abundant in the amygdala 
and hippocampus, which provide excitatory and inhibitory input to the hypothalamus, 
respectively [30, 144]. Animal models indicate that excess circulating CRH upregulates 
CRH and CRH receptor mRNA expression in these regions, with consequences for neuronal 
function and integrity [24, 142, 144]. For example, administration of CRH to the brains of 
immature rodents results in progressive loss of hippocampal neurons, which may impair 
hippocampal negative feedback regulation of the HPA axis [144]. Several human studies 
provide additional support for programming effects of placental CRH on the fetal brain, 
linking placental CRH exposures with fetal neurodevelopment [166–168] and with stress-
related outcomes in infancy and childhood [169, 170].
5. Prenatal stress exposures and postnatal HPA axis function
Programming of the developing fetal HPA axis is proposed as a plausible mechanism by 
which prenatal stress influences offspring physiological and psychological outcomes, 
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including risk for cardiovascular and metabolic disease, compromised immune function, and 
mental disorders [18–21, 171]. We review here studies in which postnatal HPA axis 
functioning is the direct outcome of interest and in which maternal prenatal stress is indexed 
directly rather than inferred from birth phenotype (for reviews of studies linking shortened 
gestation and small size at birth with altered HPA axis functioning, see refs. 21, 172, 173). 
One challenge that limits the ability to draw firm conclusions about persisting influences of 
prenatal stress exposures on HPA axis functioning is the broad range of measures of both 
prenatal stress and HPA axis functioning utilized. For this review, we conceptualize prenatal 
stress as encompassing both stress exposures, such as life events, and different physiological 
or psychological responses to stress, such as cortisol levels or symptoms of anxiety or 
depression [174]. In characterizing HPA axis functioning, some studies have considered 
basal cortisol levels at a single time point. Other investigations have measured cortisol 
response to laboratory or naturalistic stressors. Saliva samples are collected prior to the 
stressor (baseline) and at several intervals post-stressor to examine the peak and recovery of 
the cortisol response. Finally, several studies have evaluated profiles of diurnal cortisol 
output. In the mature HPA axis, cortisol levels follow a normative diurnal rhythm, with a 50–
100% increase in levels observed upon awakening (termed the cortisol awakening response, 
or CAR), peak levels approximately 30–45 minutes after awakening, and a decline in levels 
across the remainder of the day [175–177]. Table 1 summarizes these existing studies, with 
findings observed in the neonate, infant, child, adolescent, and adult. While variable in their 
methodologies and results, these studies provide strong support for the notion that prenatal 
stress programs the developing fetal HPA axis, with persisting consequences for its function.
5.1 Neonate
Several studies have assessed levels of neonatal cortisol upon or shortly after delivery. 
Neonates exposed to elevated levels of maternal depressive symptoms over the latter half of 
gestation exhibited higher levels of ACTH as compared to infants exposed to low levels of 
maternal depressive symptoms [178]. Two other investigations found that neonates of 
mothers with elevated prenatal depressive symptoms had higher levels of urinary cortisol 
[179, 180]. Only one known study to date has examined cortisol responses to a stressor in a 
neonatal sample [128]. Elevated maternal cortisol from 21 to 35 weeks’ gestation was 
associated with an exaggerated neonatal salivary cortisol response to the painful stress of the 
heel-stick blood draw, with the strongest effects observed at 25 weeks’ gestation. 
Cumulatively, these studies suggest that prenatal stress predicts heightened HPA axis activity 
during the neonatal period.
5.2 Infant
Studies that have assessed cortisol responses to routine stressors in the first several months 
of infancy and have documented elevated cortisol responses in stress-exposed infants. Stroud 
et al. [181] measured 1-month-old infants’ cortisol responses to a neurobehavioral 
examination in which the infant is observed and handled during periods of sleep, 
wakefulness, crying, and non-crying. Infants of mothers with prenatal depressive disorders 
demonstrated higher baseline cortisol levels and greater responses to the stressor, as 
compared to infants of mothers who were not depressed during their pregnancy. This effect 
was observed primarily in female infants. Furthermore, placental 11β-HSD-2 methylation 
Howland et al. Page 9
Expert Rev Endocrinol Metab. Author manuscript; available in PMC 2019 January 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
appeared to moderate these effects. Among those infants exposed to prenatal maternal 
depression, decreases in 11β-HSD-2 methylation were associated with increases in baseline 
cortisol. Tollenaar et al. [182] similarly found that higher maternal pregnancy-related anxiety 
predicted higher infant cortisol responses to a bathing session at 5 weeks of age.
There is some evidence that after the first several months of life, a developmental shift in 
HPA axis functioning occurs, and a period of hyporesponsiveness to stress is observed [183]. 
Several studies have measured cortisol responses to vaccinations or laboratory stressors in 
infants ranging from 2 to 17 months of age. These investigations, while diverse in their 
findings, on average suggest that infants exposed to higher levels of prenatal stress may 
present with greater HPA axis hypoactivity at this stage of development. A few of these 
studies have assessed infant cortisol responses to vaccination. Higher maternal pregnancy-
related anxiety was associated with decreased infant cortisol reactivity to vaccination in 2-
month-old infants [182]. Alternatively, Braithwaite et al. [184] found no effect of maternal 
prenatal depressive symptoms on cortisol response to vaccination in 2–4-month-old infants. 
Other studies have examined infant cortisol responses to standardized laboratory stressors. 
Rash [185] measured the effects of maternal prenatal diurnal cortisol output on cortisol 
response to a frustration task in 6-month-old infants. Infants who exhibited decreases in 
cortisol in response to the task (as opposed to an increase) were exposed to a flatter maternal 
diurnal profile (less of a decline in cortisol over the course of the day) at 15 weeks’ 
gestation. Another investigation examined cortisol response to the stressful still-face 
procedure in 7-month-old infants of mothers with and without prenatal anxiety disorders 
[186]. Differences in infant cortisol profiles only emerged 25–40 minutes post-stressor; 
infants of mothers without prenatal anxiety exhibited decreases in cortisol, and infants of 
mothers with prenatal anxiety displayed non-significant increases in cortisol. Finally, two 
studies have examined infant cortisol responses to a maternal separation paradigm [140, 
182]. Higher maternal pregnancy-related anxiety was associated with a lower cortisol 
response in 12-month-old infants [182], and higher amniotic fluid cortisol was associated 
with higher baseline cortisol and a blunted cortisol response in 17-month-old infants [140].
5.3 Child
Multiple studies have examined either cortisol response or diurnal cortisol output in 
childhood. All of these studies document hyperactivity of the HPA axis in children exposed 
to higher levels of prenatal stress. Elevated levels of maternal prenatal depression and 
anxiety predicted higher cortisol levels across a series of tasks in 2–5-year-old female 
children, with no differences observed in profiles of response to the tasks [187]. Higher 
prenatal maternal early morning salivary cortisol and pregnancy related-anxiety were 
associated with higher overall cortisol levels in 4–6-year-old children on the day of a 
vaccination [188] and higher overall cortisol levels in 5-year-old children on school days 
[189]. Another study measured 10-year-old children’s cortisol responses to a laboratory 
stressor and identified three cortisol profiles over the stressor: low levels with no response, 
moderate levels with no response, and high levels with response [190]. Prenatal maternal 
intimate partner violence increased the likelihood of membership in the high response group, 
as compared to the low and moderate flat groups. One additional study measured diurnal 
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cortisol output in 10-year-old children and found that higher maternal prenatal anxiety was 
associated with higher awakening cortisol levels [191].
5.4 Adolescent
A few investigations have extended examination of offspring HPA axis functioning into the 
adolescent period. Two studies assessed adolescents’ diurnal cortisol output and documented 
hypoactivity in adolescents exposed to prenatal stress. Higher maternal prenatal anxiety and 
depression predicted an altered pattern of diurnal salivary cortisol in 15-year-old children, 
reflected in a reduced cortisol awakening response and a flatter cortisol decline (smaller 
decrease from awakening to evening) over the day [192]. Similarly, elevated prenatal 
maternal anxiety was associated with a flatter diurnal cortisol decline in 14–15-year-old 
children [193]. One additional study defined prenatal stress as exposure to a disaster during 
pregnancy [194]. A birth cohort of 14-year-old Finnish twins whose mothers were pregnant 
during the Chernobyl disaster was compared with a reference group of twins whose mothers 
were pregnant one year after the disaster. Cortisol levels measured once upon arrival to a 
laboratory visit were higher in adolescents whose mothers were in their second or third 
trimester during the Chernobyl disaster, as compared to non-exposed adolescents.
5.5 Adult
Finally, one known study has examined the effects of prenatal stress, measured by maternal 
experience of a major negative life event during pregnancy, on multiple measures of HPA 
axis activity in adulthood [195]. Young adult children who reported that their mothers had 
experienced a negative life event during their pregnancy were compared with an age-
matched control group. As compared to the control group, the prenatal stress-exposed group 
exhibited hypoactivity in several domains, reflected in lower pre-stressor cortisol levels and 
lower cortisol levels during pharmacological stimulation of the pituitary via an ACTH1–24 
stimulation test. However, the prenatal stress-exposed group also exhibited increased 
reactivity to the stressor, with greater increases in cortisol in response to the stressor. No 
differences in diurnal cortisol output were exhibited between the two groups. A limitation of 
this investigation was that prenatal maternal negative life events were obtained 
retrospectively by adult children in communication with their mothers at the time of 
assessment.
5.6 Synthetic glucocorticoid exposure
Administration of synthetic glucocorticoids (GCs) is the standard of care for pregnant 
women at risk for premature delivery between 24 and 34 weeks’ gestation, because this 
treatment effectively reduces mortality and promotes lung maturation among infants born 
preterm [196, 197]. Synthetic GCs are not metabolized by placental 11β-HSD-2 and 
therefore readily cross into the placenta, where they act on developing fetal organ systems 
[198, 199]. Evidence indicates that prenatal synthetic GC exposures are associated with 
dysregulated postnatal HPA axis function. For example, compared to non-exposed preterm 
neonates, exposed preterm neonates exhibit no increases or decreases in cortisol in response 
to a heel-stick blood draw [200–203]. Because determining if preterm delivery will actually 
occur is difficult and imprecise, many women who receive synthetic GCs often go on to 
deliver beyond 37 weeks’ gestation [204]. One study demonstrated that full-term neonates 
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exposed to synthetic GCs prenatally exhibited a larger cortisol response to the heel-stick 
procedure, as compared to non-exposed neonates [205]. These effects appear to persist into 
childhood, with prenatal synthetic GC exposure predicting greater increases in cortisol in 
response to a laboratory stressor in term-born children [206] and in preterm-born 
adolescents [207]. Several studies have also documented that children and adolescents 
exposed to prenatal synthetic GCs display alterations in diurnal cortisol output, evident in an 
absence of a CAR [207, 208] and a flatter decline in cortisol over the day [208]. This 
literature provides additional support for the programming effects of excess glucocorticoids 
on long-term HPA axis function.
6. Expert commentary
A growing body of research has linked prenatal stress exposures with HPA axis functioning 
from infancy into adulthood. HPA axis dysregulation in prenatal stress-exposed individuals 
has been documented at multiple levels of functioning, including diurnal rhythms and 
responses to stress. It remains unclear as to how these different aspects of HPA axis function 
may interact or reflect similar or different markers of risk [209], particularly since studies 
have primarily focused on either diurnal rhythms or responses to stress and not their 
synergistic effects. Additionally, there is no clear consensus within the literature as to 
whether prenatal stress is associated with hyperactivity or hypoactivity of the axis. The wide 
variation in methodologies employed across these studies may in part account for the 
apparent inconsistency in findings (see ref. 209 for a relevant discussion).
It is also plausible that these discrepancies reflect meaningful developmental patterns. First, 
there is evidence that both diurnal cortisol output and cortisol response to stress vary over 
the course of development. Several studies indicate that after the first few months of infancy, 
during which stress reactivity is observed, a period of hyporesponsiveness of the stress 
system occurs, coinciding with the emergence of the diurnal rhythm of the HPA axis [183, 
210–213]. Factors like sleep patterns and quality of caregiving are proposed to underlie this 
normative developmental shift, which may persist from 2 months until midway through the 
second year of life [183, 211–213]. Interestingly, the effects of prenatal stress on infant 
cortisol response observed in the study by Tollenaar et al. [182] appear to follow this shift, 
with higher prenatal stress predicting hyperactivity at 5 weeks, and hypoactivity at 2 and 12 
months. Additional developmental changes in HPA axis functioning may occur as a result of 
puberty [214, 215]. Second, activity of the HPA axis may differ depending upon whether 
stressors are acute or chronic. Exposure to prenatal stress may result in a more reactive HPA 
axis initially, but prolonged hyperactivity may eventually result in downregulation of the 
system, with a dampening of diurnal cortisol output and hyporeactivity to stress later in life 
[183, 216, 217]. Support for this phenomenon is evident in the patterns of hypocortisolism 
observed in children and adults exposed to severe or chronic stress [183, 217]. Two of the 
studies discussed above examined diurnal cortisol output in 10-year-old [191] and 15-year-
old [192] children drawn from the same longitudinal cohort study. While there were too few 
children participating in both the 10 and 15-year follow-ups to directly test the possibility of 
a shift from hyperactivity to hypoactivity of the axis, the pattern of findings is consistent 
with such a shift.
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In terms of their characterizations of prenatal stress, investigations have focused on maternal 
psychological functioning or maternal cortisol output. A primary assumption of this research 
is that elevations in maternal and placental stress hormones mediate the effects of prenatal 
psychological stress on fetal HPA axis development. However, results of studies examining 
links between maternal prenatal psychological stress and stress hormones, primarily 
maternal cortisol, are equivocal at best (see ref. 218 for a systematic review). The 
paradoxical increase in maternal stress hormones and decrease in psychological and 
physiological responsiveness to stress as gestation advances may partly explain why 
psychological and biological markers of maternal stress are not reliably coupled. Most 
investigations have focused on individual differences between average levels of maternal 
prenatal psychological stress and stress hormones, examining whether mothers with higher 
psychological stress also exhibit higher stress hormone levels. A more precise measure of 
the concordance between psychological and physiological stress may be intra-individual 
associations between these parameters of stress. One research group has reported positive 
covariation between prenatal maternal negative mood and salivary cortisol over the course of 
the day [219, 220]. There is also some evidence that prenatal maternal psychological stress 
alters overall trajectories of cortisol output over gestation [221] and is reflected in integrated 
measures of cortisol activity, such as cortisol measured in hair [222]. It is additionally 
plausible that prenatal maternal psychological stress influences fetal HPA axis development 
through mechanisms other than prenatal maternal cortisol, such as placental CRH exposures 
or vascular or immune channels [223–227]. Research must continue to evolve and utilize a 
more comprehensive approach in understanding the variety of stress exposures that may 
influence fetal HPA axis development.
Careful consideration should also be given to factors that may moderate fetal exposure to 
prenatal stress. Particularly important may be the timing of prenatal stress. It is known that 
prenatal exposures during different gestational intervals exert differential effects, depending 
on the fetal developmental processes occurring at the time [24, 171, 228]. Furthermore, 
since maternal stress responsiveness is downregulated as gestation advances, stressful events 
experienced early in pregnancy trigger greater maternal stress responses and therefore have 
the potential to exert greater influence on the fetus than stressors experienced later in 
gestation [72–78, 229, 230].
Fetal sex also may moderate the programming effects of prenatal stress on the fetal HPA 
axis. Substantial evidence indicates that there are sex-specific trajectories of fetal 
development, related to the response of the placenta to stress [231, 232]. Female and male 
fetuses appear to exhibit contrasting growth strategies, whereby in response to stress 
exposures, female fetuses adjust their growth and male fetuses do not [232, 233]. This may 
be because the female placenta is more sensitive and responsive to changes in cortisol 
concentrations during gestation as compared to the male placenta. For example, in the 
presence of maternal inflammatory disease, female placental 11β-HSD-2 expression and 
activity are significantly decreased, with corresponding elevations in circulating cortisol 
levels and reductions in birthweight [234]. Conversely, male placental GR mRNA 
expression is increased, with no changes observed in 11β-HSD-2 activity, cortisol level, or 
growth [234]. Similarly, Osei-Kumah et al. [235] measured alterations in placental gene 
expression as a function of maternal inflammatory disease and observed many more gene 
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alterations in female placentae as compared to male placentae. Thus far, the potential 
moderating effect of fetal sex on the relationship between prenatal stress and HPA axis 
outcomes has been largely unexamined. Several studies document stronger effects of 
maternal prenatal stress on cortisol output in female children [181, 187, 191]. Additionally, 
van den Bergh et al. [193] reported an effect of maternal prenatal anxiety on diurnal salivary 
cortisol profiles in both sexes, but the altered cortisol profile was associated with depressive 
symptoms only in female adolescents. It is clear that additional research is needed to 
understand the precise mechanisms by which various prenatal stressors influence patterns of 
HPA axis development and factors that may moderate these effects.
7. Five-year view
During the fetal period, experiences and exposures shape developing organ systems to 
promote optimal functioning in life after birth. A growing number of prospective, 
longitudinal studies have assessed links between prenatal stress and later developmental 
outcomes, including HPA axis functioning. The primary focus of these existing 
investigations has been exposure to elevations in maternal psychological distress and 
maternal cortisol. Additional stress signals likely shape the developing fetal HPA axis. 
Among these is placental CRH, a direct and integrative index of fetal exposure to a variety 
of stressors. Placental CRH is upregulated by maternal and fetal cortisol, catecholomines, 
proinflammatory cytokines, and vascular changes [70, 137, 138, 153, 154, 156] and appears 
to directly influence fetal pituitary-adrenal growth and steroidogenesis [115–119]. Future 
research should focus on placental CRH as an indicator of prenatal stress-induced alterations 
in HPA axis functioning.
An emerging and promising area of research suggests that gene-environment interactions 
may also mediate the effects of prenatal stress on HPA axis development and function. 
Epigenetic mechanisms involve changes in gene expression, which can arise during critical 
periods of development in response to environmental exposures and may remain stable into 
adulthood [18, 236, 237]. Increasing evidence suggests that prenatal stress is associated with 
epigenetic change in HPA axis genes, particularly methylation in the promoter region of 
NR3C1, the gene encoding the glucocorticoid receptor [238]. As previously mentioned, GRs 
play a critical role in negative feedback inhibition of the HPA axis response. For example, 
increased methylation of NR3C1 results in decreased expression of hippocampal GR, 
dampening of HPA axis negative feedback, and a prolonged increase in circulating 
glucocorticoid levels in rodents [146]. In adult humans, childhood abuse is associated with 
increased promoter methylation and decreased expression at the NR3C1 gene in 
hippocampal brain tissue [239].
Several studies have examined links between prenatal stress and peripheral measures of 
NR3C1 methylation. Higher levels of prenatal maternal depression and anxiety [240, 241] 
and diurnal cortisol output [241] were associated with increased methylation of NR3C1 in 
cord blood, which predicted increased infant cortisol response to stress at 3 months [240]. 
Elevations in prenatal maternal depression and anxiety also predicted increased placental 
NR3C1 and 11β-HSD-2 methylation [242]. One study considered the impact of prenatal 
exposure to chronic stress and war-related trauma in a sample of mothers and infants in the 
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Democratic Republic of Congo, documenting methylation of multiple genes regulating HPA 
axis function (CRH, CRHBP, NR3C1, and FKBP5) in maternal blood, cord blood, and 
placental tissue [243]. There is some evidence that the effects of prenatal-induced epigenetic 
modifications may extend into adolescence and adulthood [244] and may be further 
transmitted across multiple generations [245]. While the relationship between epigenetic 
variation in the periphery and in brain is currently unknown, these findings encourage 
further examination of the interactive influence of genes and environmental stressors on 
HPA axis development.
Finally, future research could examine how the pre and postnatal environments act 
independently or synergistically to shape development of the HPA axis. A few investigations 
have considered the additive or moderating effects of the postnatal environment on stress 
responsiveness [186, 246–249]. Kaplan et al. [249] reported that postnatal maternal 
sensitivity moderated the effects of prenatal maternal mood disorder on baseline cortisol in 
4-month-old infants. Specifically, infants of mothers with a prenatal maternal mood disorder 
exhibited elevated cortisol only in context of low maternal sensitivity, and infants of mothers 
without a prenatal maternal mood disorder had low cortisol regardless of maternal 
sensitivity. In this sense, the effects of prenatal stress may be amplified in context of an 
impoverished postnatal environment or may be attenuated in a high-quality environment. 
The predictive adaptive response hypothesis alternatively posits that developmental 
adjustments made in response to prenatal stress signals are adaptive when the actual 
postnatal environment matches that predicted by the prenatal environment [4, 5, 8]. 
Consistent with this argument, one study indicated that infants exhibited more extreme 
salivary cortisol responses to a maternal separation stressor, reflected in an extended 
response and lack of recovery, if maternal prenatal and postnatal depressive symptom levels 
were discordant [247]. Infants exposed to consistently low levels of depressive symptoms 
exhibited the most normative profiles of response and recovery from the stressor. 
Collectively, these studies provide additional evidence that the developing fetal HPA axis is 
sensitive to and shaped by the conditions of the intrauterine environment, but additionally 
suggest that the effects of prenatal stress exposures should be considered in the context of 
the postnatal environment.
While the multiple complex mechanisms regulating the development of the fetal HPA axis 
are not fully understood, studies reviewed here provide strong evidence that prenatal stress 
exposures shape the developing axis and exert persisting influence on its function into 
adulthood. Given the fundamental role of the HPA axis in regulating many of the body’s 
homeostatic systems and associations between HPA axis dysregulation and disease [9–15], 
programming of the axis is a plausible mechanism underlying links between early exposures 
and later health outcomes, including risk for cardiovascular, metabolic, immune, and mental 
disorders [3, 16–22]. The HPA axis is an ancient physiological system that has been 
maintained by natural selection and conserved across species, promoting adaptation and 
survival in response to environmental threats [250]. The sensitivity and plasticity of the 
developing fetal HPA axis stress to exposures signaling the state of the external environment 
also appears to be deeply rooted in human evolutionary history [251] and would have been 
of value to our ancestors, ensuring offspring would be well-suited to survive in a presumably 
limiting and hostile environment [4, 5]. However, activation of this same stress reponse 
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system may no longer be adaptive in modern environments characterized by urbanization, 
nutritional abundance, and a sedantary lifestyle, in which stressors are frequent and chronic 
but seldom require fight or flight [252, 253]. Stress related-alterations in physiology may 
instead prove detrimental to health and confer risk for disease. Interventions focused on 
improving the quality of maternal and fetal health in utero may assist in closing the gap 
between the stress responses conferred on us by our evolutionary past and those better suited 
for modern day circumstances.
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8. Key issues
• The developmental origins of disease or fetal programming model predicts 
that prenatal experiences have life-long consequences for physical and 
psychological health.
• The hypothalamic-pituitary-adrenal (HPA) axis mobilizes the body’s physical 
and psychological resources in response to stress and regulates many 
homeostatic systems. Programming of the developing fetal HPA axis is 
proposed as a primary mechanism by which early experiences are linked to 
later disease risk.
• The placenta is largely responsible for the massive changes that occur in both 
the maternal and developing fetal stress systems during the prenatal period. 
An integrated maternal-placental-fetal steroidogenic unit regulates the 
prenatal endocrine milieu.
• The precise mechanisms by which prenatal stressors may shape the nascent 
fetal HPA axis are not fully understood. In addition to cortisol, placental CRH 
is a promising candidate, because it is a signal that integrates a variety of 
stressors and appears to directly influence fetal pituitary-adrenal activity.
• Prospective, longitudinal investigations have provided evidence that 
elevations in maternal prenatal psychological stress and cortisol are associated 
with alterations in HPA axis functioning, reflected in diurnal rhythms and 
responses to stress. Findings are observed in the neonate, infant, child, 
adolescent, and adult.
• Prenatal stress is associated with both hyperactivity or hypoactivity in HPA 
axis functioning. It is also plausible that these differential effects reflect 
meaningful developmental patterns.
• Several factors may moderate the effects of prenatal stress on HPA axis 
function, including the time of gestation at which the stressor occurs and the 
sex of the fetus.
• An emerging literature suggests that epigenetic changes in HPA axis genes 
may mediate the effects of prenatal stress on fetal HPA axis development and 
function.
• The effects of prenatal stress may be amplified or attenuated as a function of 
the postnatal environment. Alternatively, the predictive adaptive response 
hypothesis posits that developmental adjustments made in response to 
prenatal stress are adaptive if there is a match between the prenatal and 
postnatal environments.
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Figure 1. 
Schematic representation of the hypothalamic-pituitary-adrenal (HPA) axis. In response to 
stress, corticotropin-releasing hormone (CRH) is synthesized in the paraventricular nucleus 
(PVN) of the hypothalamus and released into the hypophyseal portal blood. CRH binds to its 
receptors on pituitary corticotropes, stimulating the release of adrenocorticotrophic hormone 
(ACTH). Circulating ACTH binds to its receptors in the adrenal cortex and stimulates the 
release of cortisol, which mobilizes body systems to respond to the stressor. Elevated 
circulating cortisol inhibits further HPA axis activity (blue squares) by binding to its two 
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receptor types, glucocorticoid receptors (GRs) and mineralocorticoid receptors (GRs), at the 
level of the hypothalamus, pituitary, and hippocampus. CRH-producing neurons in the PVN 
of the hypothalamus are innervated by afferent projections from multiple brain regions (blue 
and green circles), including the amygdala, which provides excitatory input, and the 
prefrontal cortex and hippocampus, which provide inhibitory input.
ACTH: Adrenocorticotropic hormone; CRH: Corticotropin-releasing hormone; GR: 
glucocorticoid receptor; MR: mineralocorticoid receptor; PVN: paraventricular nucleus
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Figure 2. 
Increases in hypothalamic-pituitary-adrenal and placental hormones in maternal circulation 
over gestation. Points represent mean levels of these hormones at each gestational interval.
ACTH: Adrenocorticotropic hormone; CRH: Corticotropin-releasing hormone; GA: 
Gestational age
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Figure 3. 
Schematic representation of the maternal-placental-fetal steroidogenic unit. Placental 
corticotropin-releasing hormone (CRH) influences both maternal and fetal stress hormone 
production. In the maternal compartment, increases in placental CRH promote increased 
synthesis and release of ACTH and cortisol. Maternal cortisol in turn stimulates placental 
CRH production, generating a positive feedback loop (green lines). The placental enzyme 
11β-hydroxysteroid dehydrogenase 2 (11β-HSD-2) oxidizes maternal cortisol into cortisone, 
but it is only a partial barrier, with some maternal cortisol entering fetal circulation. The 
developing fetal hypothalamic-pituitary-adrenal axis is regulated in part by maternal cortisol 
and placental CRH. Maternal cortisol may inhibit fetal pituitary ACTH release. Placental 
CRH likely stimulates production of fetal cortisol, both by increasing fetal adrenal 
responsiveness to ACTH and by direct stimulation of the adrenal. Increased fetal cortisol 
would in turn stimulate placental CRH production, constituting a second positive feedback 
loop (green lines). The massive amounts of hormones produced by the maternal-placental-
fetal unit benefit both mother and fetus and influence the timing of parturition.
ACTH: Adrenocorticotropic hormone; CRH: Corticotropin-releasing hormone; 11β-HSD-2: 
11β-hydroxysteroid dehydrogenase 2
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Figure 4. 
Time table summarizing fetal hypothalamic-pituitary adrenal (HPA) axis development.
ACTH: Adrenocorticotropic hormone; CRH: Corticotropin-releasing hormone; 11β-HSD-2: 
11β-hydroxysteroid dehydrogenase 2
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Table 1.
Studies documenting associations between prenatal stress and postnatal HPA axis functioning
Study Sample Prenatal Exposure HPA Axis Outcome Findings
Neonate
Davis et al. 
(2011)
116 women and 
their neonates
Maternal cortisol and 
psychosocial stress at 15, 19, 25, 
31, and 37 weeks’ gestation
Salivary cortisol response to 
heel-stick blood draw at 
approximately 24 hours after 
birth; samples collected pre-
stressor and at 20 and 40 min 
post-stressor
Elevated maternal cortisol 
from 21–35 weeks’ gestation 
was associated with larger 
neonatal cortisol response; 
strongest effects were at 25 
weeks’ gestation
Field et al. 
(2004)
119 women and 
their neonates
Maternal depressive symptoms 
and first morning urinary 
cortisol at approximately 20 
weeks’ gestation
Urinary cortisol within 24 hours 
of delivery
Neonates of mothers with 
elevated depressive 
symptoms had higher 
cortisol levels
Lundy et al. 
(1999)
63 women and 
their neonates
Maternal depressive symptoms 
and urinary cortisol during third 
trimester (M = 32 weeks’ 
gestation, range = 27–35 weeks’ 
gestation)
Urinary cortisol within 24 hours 
of delivery
Neonates of mothers with 
elevated depressive 
symptoms had higher 
cortisol levels
Marcus et al. 
(2011)
154 women and 
their neonates
Maternal depressive symptoms 
at 28, 32, and 37 weeks’ 
gestation
ACTH and cortisol levels from 
umbilical cord artery blood at 
delivery
Neonates exposed to elevated 
levels of maternal depressive 
symptoms had higher ACTH 
levels than neonates exposed 
to low-stable depressive 
symptoms
Infant
Braithwaite, 
Murphy, & 
Ramchandani 
(2016)
88 women and 
their 2–4-month-
old infants
Maternal depressive symptoms 
during second or third trimester 
(M = 28 weeks’ gestation; range 
= 15–41 weeks’ gestation)
Salivary cortisol response to 
inoculation; samples collected 
anytime in day before stressor, 
immediately after stressor, and 
at 20 and 40 min post-stressor
No association between 
maternal depressive 
symptoms and infant cortisol 
response
Grant et al. 
(2009)
88 women and 
their 7-month-old 
infants
Maternal anxiety symptoms 
assessed via structured clinical 
interview during last trimester of 
pregnancy; women classified as 
meeting (or not meeting) criteria 
for prenatal anxiety disorder 
during last six months of 
pregnancy
Salivary cortisol response to the 
still-face procedure; samples 
collected at pre-stressor and at 
15, 25, and 40 min post-stressor
Infants of mothers without 
prenatal anxiety disorders 
exhibited decrease in cortisol 
from 25–40 minutes post-
stressor, while infants of 
mothers with prenatal 
anxiety disorders exhibited 
non-significant increase in 
cortisol across this interval
O’Connor et al. 
(2012)
125 women and 
their 17-month-old 
infants
Amniotic fluid cortisol during 
second or third trimester (M = 
17 weeks’ gestation; range = 
15–37 weeks’ gestation)
Salivary cortisol response to a 
maternal separation paradigm; 
samples collected pre-stressor 
and at 20 minutes post-stressor
Infants exposed to higher 
levels of amniotic fluid 
cortisol exhibited higher pre-
stress cortisol levels and 
blunted stress responses 
(slight decrease over 
stressor)
Rash et al. 
(2016)
254 women at 
their 6-month-old 
infants
Maternal diurnal salivary 
cortisol output (4 samples over 2 
consecutive days) and 
psychosocial stress at 15 weeks’ 
and 32 weeks’ gestation
Salivary cortisol response to set 
of structured laboratory 
frustration tasks at 6 months; 
samples collected pre-stressor 
and at approximately 15 minutes 
post-stressor
Infants who exhibited a 
decreased in cortisol in 
response to the task (as 
opposed to an increase) were 
exposed to a flatter maternal 
diurnal profile (less of a 
decline in cortisol over the 
course of the day) at 15 
weeks’ gestation
Stroud et al. 
(2016)
153 women and 
their 1-month-old 
infants
Maternal depressive symptoms 
assessed via structured clinical 
interview at approximately 23, 
30, and 36 weeks’ gestation; 
women classified as exhibiting 
prenatal depressive disorder, 
preconception-only depressive 
Salivary cortisol response to 
NICU Network Neurobehavioral 
Scale; samples collected pre-
stressor, end of stressor, and at 
20 and 40 minutes post-stressor
Infants of mothers with 
prenatal depressive disorders 
exhibited higher baseline 
cortisol levels and higher 
cortisol response than infants 
of mothers with pre-
conception only or no 
depressive disorders (effect 
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disorder, or no depressive 
disorder
was driven by female 
infants); among infants of 
mothers with prenatal 
depressive disorders, 
decreased placental 11β-
HSD-2 methylation 
associated with increased 
baseline cortisol levels
Tollenaar et al. 
(2011)
173 women and 
their infants 
(assessed at 5 
weeks, 8 weeks, 5 
months, and 12 
months)
Maternal anxiety, daily hassles, 
pregnancy related anxiety, and 
dirunal salivary cortisol output 
(5 samples per day over 2 
consecutive days) during third 
trimester (M = 37 weeks)
Salivary cortisol response to a 
bathing session at 5 weeks, 
vaccination at 8 weeks, still-face 
procedure at 6 months, and 
maternal separation paradigm at 
12 months; samples collected 
pre-stressor and at 25 and 40 
minutes post-stressor
Higher pregnancy-related 
anxiety predicted higher 
infant cortisol response to 
stressor at 5 weeks and lower 
cortisol response to stressors 
at 8 weeks and 12 months
Child
de Bruijn et al. 
(2009)
103 women and 
their 2–5-year-old 
children
Maternal anxiety and depressive 
symptoms at 12, 24, and 36 
weeks’ gestation; children 
whose mothers scored above a 
standardized cutoff or higher 
than 1 SD above the sample 
mean on one of the three 
measurements of anxiety or 
depression at any of the 
gestational intervals classified as 
the prenatally exposed group
Salivary cortisol response to a 
mother-child play task and a 
frustration task; samples 
collected at start of home visit, 
and at 22 minutes after each task
No differences in response 
patterns between prenatally 
exposed and non-exposed 
children, with both groups 
showing a decrease in 
cortisol levels over the tasks; 
among female children, 
higher overall cortisol levels 
in prenatally exposed; no 
effects among male children
Gutteling, de 
Weerth, & 
Buitelaar (2004)
24 women and 
their 4–6-year-old 
children
Maternal pregnancy-related 
anxiety, daily hassles, perceived 
stress, and early morning 
cortisol levels at 15–17 weeks’ 
gestation; children placed in low 
and high prenatal stress groups 
by median split for each of the 
four prenatal stress measures
Salivary cortisol response to 
vaccination; samples collected 
pre-stressor and at 15, 20, 25, 
and 30 minutes post-stressor
Higher maternal prenatal 
daily hassles, pregnancy-
related anxiety, and early 
morning cortisol levels were 
associated with higher 
overall child cortisol levels
Gutteling, de 
Weerth, & 
Buitelaar (2005)
29 women and 
their 5-year-old 
children
Maternal pregnancy-related 
anxiety, daily hassles, perceived 
stress, and early morning 
cortisol levels at 15–17 weeks’ 
gestation; children placed in low 
and high prenatal stress groups 
by median split for each of the 
four prenatal stress measures
Diurnal salivary cortisol output 
on weekend day (5 samples over 
the day), on the first day of 
school (4 samples over the day), 
and on a school day one week 
later (4 samples over the day)
Higher maternal pregnancy-
related anxiety and early 
morning cortisol levels were 
associated with higher 
overall child cortisol levels 
on school days
Martinez-
Torteya et al. 
(2016)
N = 119 women 
and their 10-year-
old children
Third trimester (M = 33 weeks’ 
gestation) maternal report of 
exposure to intimate partner 
violence (IPV) during pregnancy
Salivary cortisol response to 
Trier Social Stress Test for 
Children; samples collected pre-
stressor and at 20 and 40 
minutes post-stressor
Identified three profiles of 
child cortisol response: 
consistently low levels, 
consistently moderate levels, 
and consistently high levels 
with increase from pre-
stressor to 20 min post-
stressor; exposure to 
maternal prenatal IPV 
increased likelihood of 
membership in high response 
group, as compared to 
consistently low and 
moderate response groups
Child
O’Connor et al. 
(2005)
74 women and 
their 10-year-old 
children
Maternal anxiety and depressive 
symptoms at 18 and 32 weeks’ 
gestation
Diurnal salivary cortisol output 
(4 samples per day over 3 
consecutive days
Higher maternal prenatal 
anxiety at 32 weeks’ 
gestation predicted higher 
child awakening cortisol 
levels
Adolescent
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Huizink et al. 
(2008)
121 14-year-old 
twin pairs of 
Finnish women 
pregnant during 
the Chernobyl 
disaster and 157 
14-year-old twin 
pairs of women 
who were 
pregnant one year 
after the disaster
Exposed or not exposed to 
Chernobyl disaster during 
pregnancy
Salivary cortisol levels measured 
once upon arrival to a laboratory 
visit
Adolescents whose mothers 
were in their second or third 
trimesters during the 
Chernobyl disaster had 
higher cortisol levels as 
compared to the reference 
group
O’Donnell et al. 
(2013)
899 women and 
their 15-year-old 
adolescents
Maternal anxiety and depressive 
symptoms at 18 and 32 weeks’ 
gestation
Diurnal salivary cortisol output 
(4 samples per day over 3 
consecutive days)
Higher maternal prenatal 
anxiety and depressive 
symptoms were associated 
with a lower cortisol 
awakening response and a 
flatter diurnal decline 
(smaller decrease) in cortisol 
levels in adolescents; effects 
similar at 18 & 32 weeks’ 
gestation
Van den Bergh 
et al. (2008)
58 women and 
their 14–15-year 
old adolescents
Maternal anxiety symptoms at 
12–22, 23–32, and 32–40 
weeks’ gestation
Diurnal salivary cortisol output 
(3 samples over one day)
Elevated prenatal maternal 
anxiety at 12–22 weeks’ 
gestation was associated with 
a flatter diurnal decline 
(smaller decrease) in cortisol 
levels in adolescents; in 
female adolescents this 
cortisol profile was 
associated with higher 
depressive symptoms
Adult
Entringer et al. 
(2009)
31 young adults 
whose mothers 
reported 
experiencing a 
major negative life 
event during 
pregnancy and a 
control group of 
30 age-matched 
young adults
Maternal prenatal life events 
were obtained retrospectively by 
young adult children in 
communication with mothers at 
time of the assessment
ACTH and serum cortisol 
responses to Trier Social Stress 
Test (samples pre-stressor and at 
15, 25, 35, and 105 minutes 
post-stressor), pharmacological 
stimulation of pituitary 
(ACTH1–24 test), and diurnal 
salivary cortisol output (20 
samples over one weekday)
Prenatal stress-exposed 
group exhibited lower 
baseline cortisol levels and 
greater increases in cortisol 
(baseline to peak) in 
response to stressor, as well 
as trend-level higher ACTH 
levels during the stressor; 
prenatal stress-exposed 
group exhibited lower 
cortisol levels during 
ACTH1–24 test; no 
differences in diurnal cortisol 
output between the two 
groups
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